Based on the Oncolytics Biotech Inc stock forecast from 1 analysts, the average analyst target price for Oncolytics Biotech Inc is USD 5.00 over the next 12 months. Oncolytics Biotech Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Oncolytics Biotech Inc is Very Bearish, which is based on 0 positive signals and 6 negative signals. At the last closing, Oncolytics Biotech Inc’s stock price was USD 0.98. Oncolytics Biotech Inc’s stock price has changed by -8.41% over the past week, -23.44% over the past month and -34.67% over the last year.
No recent analyst target price found for Oncolytics Biotech Inc
No recent average analyst rating found for Oncolytics Biotech Inc
Company Overview Oncolytics Biotech Inc
Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada. Read Less
Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clin...Read More
Frequently Asked Questions About Oncolytics Biotech Inc (ONCY) Stock
Based on ratings from 1 analysts Oncolytics Biotech Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Very Bearish. The stock has 3 buy, sell and hold ratings.
Unfortunately we do not have enough data on ONCY's stock to indicate if its a good dividend stock.
Based on targets from 1 analysts, the average taret price for ONCY is USD 5.00 over the next 12 months. The maximum analyst target price is USD 5 while the minimum anlayst target price is USD 5.
Unfortunately we do not have enough data on ONCY's stock to indicate if its overvalued.
The last closing price of ONCY's stock was USD 0.98.
The most recent market capitalization for ONCY is USD 0.09B.
Based on targets from 1 analysts, the average taret price for ONCY is projected at USD 5.00 over the next 12 months.
This means that ONCY's stock price may go up by +410.20% over the next 12 months.
We can't find any ETFs which contains Oncolytics Biotech Inc's stock.
As per our most recent records Oncolytics Biotech Inc has 0 Employees.
Oncolytics Biotech Inc's registered address is 322 11th Avenue SW, Calgary, AB, Canada, T2R 0C5.
You can get more information about it from Oncolytics Biotech Inc's website at https://www.oncolyticsbiotech.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
There is nothing we particularly like
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Frequently Asked Questions About Oncolytics Biotech Inc (ONCY) Stock
Based on ratings from 1 analysts Oncolytics Biotech Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Very Bearish. The stock has 3 buy, sell and hold ratings.
Unfortunately we do not have enough data on ONCY's stock to indicate if its a good dividend stock.
Based on targets from 1 analysts, the average taret price for ONCY is USD 5.00 over the next 12 months. The maximum analyst target price is USD 5 while the minimum anlayst target price is USD 5.
Unfortunately we do not have enough data on ONCY's stock to indicate if its overvalued.
The last closing price of ONCY's stock was USD 0.98.
The most recent market capitalization for ONCY is USD 0.09B.
Based on targets from 1 analysts, the average taret price for ONCY is projected at USD 5.00 over the next 12 months.
This means that ONCY's stock price may go up by +410.20% over the next 12 months.
We can't find any ETFs which contains Oncolytics Biotech Inc's stock.
As per our most recent records Oncolytics Biotech Inc has 0 Employees.
Oncolytics Biotech Inc's registered address is 322 11th Avenue SW, Calgary, AB, Canada, T2R 0C5.
You can get more information about it from Oncolytics Biotech Inc's website at https://www.oncolyticsbiotech.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for ONCY !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
